Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0P6DJ
|
|||
| Former ID |
DNC005636
|
|||
| Drug Name |
VATALANIB
|
|||
| Synonyms |
Vatalanib; 212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 2 | [1], [2] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H15ClN4
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C(=NN=C2NC3=CC=C(C=C3)Cl)CC4=CC=NC=C4
|
|||
| InChI |
1S/C20H15ClN4/c21-15-5-7-16(8-6-15)23-20-18-4-2-1-3-17(18)19(24-25-20)13-14-9-11-22-12-10-14/h1-12H,13H2,(H,23,25)
|
|||
| InChIKey |
YCOYDOIWSSHVCK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 212141-54-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
8034494, 10318716, 11544568, 14827532, 46227754, 47207942, 50070546, 50071177, 50100112, 53790491, 57347324, 58107197, 77174846, 91616548, 92308747, 93619729, 93692965, 103317292, 103905548, 104171421, 104430401, 121264549, 125344798, 126652555, 126681092, 127342265, 127342266, 129776330, 131305145, 134339000, 134342841, 135141434, 136367735, 137001820, 142433490, 144206361, 152035902, 162187512, 162814431, 163790606, 164041949, 164235383, 164766095, 164830894, 165222126, 165238043, 165998596, 170466113, 172916394, 175426883
|
|||
| ChEBI ID |
CHEBI:90620
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5705). | |||
| REF 2 | ClinicalTrials.gov (NCT00348790) Vatalanib in Treating Patients With Recurrent or Progressive Meningioma. U.S. National Institutes of Health. | |||
| REF 3 | Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cyst... Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. | |||
| REF 4 | Discovery and evaluation of 2-anilino-5-aryloxazoles as a novel class of VEGFR2 kinase inhibitors. J Med Chem. 2005 Mar 10;48(5):1610-9. | |||
| REF 5 | Inhibitors of VEGF receptors-1 and -2 based on the 2-((pyridin-4-yl)ethyl)pyridine template. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1913-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.